T
Toni K. Choueiri
Researcher at Harvard University
Publications - 1230
Citations - 84800
Toni K. Choueiri is an academic researcher from Harvard University. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 107, co-authored 1071 publications receiving 59514 citations. Previous affiliations of Toni K. Choueiri include University of Ulsan & University of British Columbia.
Papers
More filters
Journal ArticleDOI
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
Jean-Christophe Pignon,Opeyemi Jegede,Sachet A. Shukla,David A. Braun,Christine Horak,Megan Wind-Rotolo,Yuko Ishii,Paul J. Catalano,Jonian Grosha,Abdallah Flaifel,Jesse Novak,Kathleen M. Mahoney,Kathleen M. Mahoney,Gordon J. Freeman,Arlene H. Sharpe,F. Stephen Hodi,Robert J. Motzer,Toni K. Choueiri,Catherine J. Wu,Michael B. Atkins,David F. McDermott,Sabina Signoretti,Sabina Signoretti +22 more
TL;DR: Improved association of candidate biomarkers for nivolumab response with endpoints defined by irRECIST compared with RECISTv1.1 was observed, and combination of TC PD-L1 expression in combination with PD-1 expression on CD8+ TIC may predict outcome on nivlumab in mccRCC.
Journal ArticleDOI
Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia
TL;DR: A patient with acute myeloid leukemia whose febrile neutropenia was treated with daptomycin and who later developed daptomecin-resistant Enterococcus faecium infection is described.
Journal ArticleDOI
Influence of Androgen Deprivation Therapy on All-Cause Mortality in Men With High-Risk Prostate Cancer and a History of Congestive Heart Failure or Myocardial Infarction
Paul L. Nguyen,Ming-Hui Chen,Joshua A. Beckman,Clair J. Beard,Neil E. Martin,Toni K. Choueiri,Jim C. Hu,Karen E. Hoffman,Daniel E. Dosoretz,Brian J. Moran,Sharon Salenius,Michelle H. Braccioforte,Philip W. Kantoff,Anthony V. D'Amico,Ronald D. Ennis +14 more
TL;DR: Although ADT has been shown in Phase III studies to improve overall survival in high- risk disease, the small subgroup of high-risk patients with a history of CHF or MI, who represented about 9% of the patients, may be harmed by ADT.
Journal ArticleDOI
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
M. Dror Michaelson,Rana R. McKay,Lillian Werner,Michael B. Atkins,Eliezer M. Van Allen,Kara M. Olivier,Jiaxi Song,Sabina Signoretti,David F. McDermott,Toni K. Choueiri +9 more
TL;DR: The objective of this study was to investigate the efficacy of antiangiogenic therapy in combination with cytotoxic chemotherapy in clinically aggressive RCC.
Journal ArticleDOI
Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States
Ayal A. Aizer,Xiangmei Gu,Ming-Hui Chen,Toni K. Choueiri,Neil E. Martin,Jason A. Efstathiou,Andrew S. Hyatt,Powell L. Graham,Quoc-Dien Trinh,Jim C. Hu,Paul L. Nguyen +10 more
TL;DR: Overtreatment of low-risk prostate cancer is partially driven by sociodemographic factors and occurs frequently, with marked impact on patient quality of life and health-related costs.